TY - JOUR
T1 - TRPV1 polymorphisms and risk of interferon β-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis
AU - Buttari, Fabio
AU - Zagaglia, Sara
AU - Marciano, Lorenzo
AU - Albanese, Maria
AU - Landi, Doriana
AU - Nicoletti, Carolina Gabri
AU - Mercuri, Nicola Biagio
AU - Silvestrini, Mauro
AU - Provinciali, Leandro
AU - Marfia, Girolama Alessandra
AU - Mori, Francesco
AU - Centonze, Diego
PY - 2017/4/15
Y1 - 2017/4/15
N2 - Interferon-β (IFN-β) is often discontinued in RRMS patients due to its most common side effect, the flu-like syndrome (FLS). The mechanisms underlying IFN β-induced FLS symptoms are still unclear. The endocannabinoid system (ECS) is a key regulator of pain and inflammation. Thus we tested the hypothesis that the ECS could be involved in FLS severity by exploring the effect of genetic polymorphisms with functional impact on the ECS, on patient-reported FLS symptoms. GG-carriers of the transient-receptor-potential-vanilloid-1 (TRPV1) single nucleotide polymorphism rs222747 reported greater pain and weakness during FLS. This study suggests that the TRPV1 channel is involved in FLS severity.
AB - Interferon-β (IFN-β) is often discontinued in RRMS patients due to its most common side effect, the flu-like syndrome (FLS). The mechanisms underlying IFN β-induced FLS symptoms are still unclear. The endocannabinoid system (ECS) is a key regulator of pain and inflammation. Thus we tested the hypothesis that the ECS could be involved in FLS severity by exploring the effect of genetic polymorphisms with functional impact on the ECS, on patient-reported FLS symptoms. GG-carriers of the transient-receptor-potential-vanilloid-1 (TRPV1) single nucleotide polymorphism rs222747 reported greater pain and weakness during FLS. This study suggests that the TRPV1 channel is involved in FLS severity.
KW - Cannabinoid
KW - CB1
KW - Endocannabinoid system
KW - FAAH
KW - Pain
KW - SNP
UR - http://www.scopus.com/inward/record.url?scp=85013762440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013762440&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2017.02.007
DO - 10.1016/j.jneuroim.2017.02.007
M3 - Article
C2 - 28284340
AN - SCOPUS:85013762440
VL - 305
SP - 172
EP - 174
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
SN - 0165-5728
ER -